Developing a COVID-19 Vaccine Quickly Proving to be a Daunting Task But Progress Still Expected
June 5, 2020
Palm Beach, FL – Rapid development of a vaccine to prevent the global health crisis is a global imperative, and defining the stakes and potential hurdles is critical because regulatory and medical decisions are based on benefit/risk calculations.
The benefit of developing an effective vaccine is very high, and even greater if it can be deployed in time to prevent repeated or continuous epidemics.
Coronavirus
First Detailed Analysis Of Immune Response To SARS-CoV-2 Bodes Well For COVID-19 Vaccine Development
May 17, 2020
La Jolla, CA – Scientists around the world are racing to develop a vaccine to protect against COVID-19 Coronavirus infection, and epidemiologists are trying to predict how the coronavirus pandemic will unfold until such a vaccine is available.
Yet, both efforts are surrounded by unresolved uncertainty whether the immune system can mount a substantial and lasting response to SARS-CoV-2 and whether exposure to circulating common cold coronaviruses provides any kind of protective immunity.
Study finds robust antiviral T cell response in humans with COVID-19 Coronavirus and detects substantial crossreactivity in unexposed individuals; in a piece of good news provides a benchmark for testing of vaccine candidates.
Voltron Therapeutics announces Selection of First Two Sets of Virus Targeting Peptides for Animal Testing in the Development of a COVID-19 Vaccine
April 27, 2020
New York – Voltron Therapeutics, Inc. has announced that it has selected the peptides required to complete the structure of HaloVax for development and progression into pre-clinical animal testing of the HaloVax Self-Assembling Vaccine (SAV).
Candidate selected to initiate testing of HaloVax™, a Self-Assembling Vaccine to protect people at risk of COVID-19 Coronavirus infection.
FDA Coronavirus (COVID-19) Update: April 18th, 2020
April 18, 2020
Silver Spring MD – The U.S. Food and Drug Administration (FDA) has announced the following actions taken in its ongoing response effort to the COVID-19 Coronavirus pandemic:
The National Institutes of Health (NIH) and the Foundation for the NIH announced a public-private partnership with the FDA and others to speed the development of COVID-19 Coronavirus vaccine and treatment options.
Coronavirus
15 Prominent Pharma Companies in Vaccine Developments for COVID-19
April 7, 2020
Dublin – Coronavirus (COVID-19) is spreading throughout the world and vaccine developers have responded with unprecedented speed.
Since the Coronavirus (COVID-19) genome sequence was released in January, human trials of Moderna’s vaccine candidate have already begun.
15 Prominent Pharma Companies in Vaccine Developments for Coronavirus (COVID-19). (ResearchAndMarkets.com)
INOVIO Initiates Phase 1 Clinical Trial Of Its COVID-19 Vaccine, Plans First Dose Today
April 6, 2020
Plymouth Meeting, PA – INOVIO Pharmaceuticals, Inc. (NASDAQ:INO) today, Monday, April 6th, 2020, announced that the U.S. Food and Drug Administration (FDA) has accepted the company’s Investigational New Drug (IND) application for INO-4800, its DNA vaccine candidate designed to prevent Coronavirus (COVID-19) infection, paving the way for Phase 1 clinical testing of INO-4800 in healthy volunteers beginning this week. The first dosing is planned for today.
Coronavirus
Johnson & Johnson Announces a Lead Vaccine Candidate for COVID-19
March 30, 2020
Landmark New Partnership with U.S. Department of Health & Human Services; and Commitment to Supply One Billion Vaccines Worldwide for Emergency Pandemic Use
New Brunswick, NJ – Johnson & Johnson (NYSE: JNJ) (the Company) today, Monday, March 30th, 2020, announced the selection of a lead coronavirus (COVID-19) vaccine candidate from constructs it has been working on since January 2020.
Coronavirus.
